
Bayer Watch 63E
Bayer, the pharmaceutical group, is nearing deals to resolve 50,000 to 85,000 of 125,000 U.S. cancer lawsuits over the use of its Roundup weedkiller
Share this:
The settlements still need approval from the company’s supervisory board, in June.
Chris Loder, a U.S.-based spokesman for Bayer said “As we have said previously, the company will consider a resolution if it is financially reasonable and provides a process to resolve potential future litigation.”
From a technical perspective, the stock price has landed on a support at 55.3E (Lower Bollinger band + 50DMA) and is posting a rebound. The bullish gap opened above the 20DMA is a positive signal. However, the stock price remains stuck in trading range on a short term basis between 55.3E and 63E.
A breakout confirmation of 63E would confirm the bullish outlook with 68E as target.
Alternatively, a push below 55.3E would reinstate a bearish bias towards 50E.
Source: GAIN Capital, TradingView
The settlements still need approval from the company’s supervisory board, in June.
Chris Loder, a U.S.-based spokesman for Bayer said “As we have said previously, the company will consider a resolution if it is financially reasonable and provides a process to resolve potential future litigation.”
From a technical perspective, the stock price has landed on a support at 55.3E (Lower Bollinger band + 50DMA) and is posting a rebound. The bullish gap opened above the 20DMA is a positive signal. However, the stock price remains stuck in trading range on a short term basis between 55.3E and 63E.
A breakout confirmation of 63E would confirm the bullish outlook with 68E as target.
Alternatively, a push below 55.3E would reinstate a bearish bias towards 50E.
Source: GAIN Capital, TradingView
Related tags:
Latest market news
View more newsOpen an account today
Experience award-winning platforms with fast and secure execution.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.

ASX 200 On Track for Worst Week in Four Years, Raising Bear Market Fears
The ASX 200 faces its worst week in four years as falling commodities, China's economic weakness and broad-based selling threaten a deeper correction.

British Pound Short-term Outlook: GBP/USD 3% Plunge Hits 12-Month Low—Key Support in Focus 11 19 2026
Sterling’s October rebound has unraveled, leaving GBP/USD bears in control—but stretched momentum raises the stakes for the weekly close

Australian Dollar Technical Outlook: AUD/USD 6% Plunge Tests Make-or-Break Support at Yearly Low 11 19 2026
AUD/USD’s four-week decline is testing critical support, with a decisive break below this threshold needed to fuel the next major leg lower.
From time to time, StoneX Financial Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.
As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.




